Month: May 2022

HALIFAX, Nova Scotia, May 20, 2022 (GLOBE NEWSWIRE) — Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on the Company’s regulatory work for Canada for its VYRA™ product line. On the 10th of May 2022, Health Canada issued to all stakeholder further information about the current Interim Order No. 3. As a result, the regulators have clearly defined the pathway to achieve the Interim Order and with it provided the Company with the last requirement to complete its final application for their review. The final condition for MedMira is to complete an additional Canadian based clinical study to supplement its existing data. At this stage, MedMira has engaged a renowned third-party in Canada and already forwarded the clinical protocol to the Ethics Committee for acceptance. At the time of receiving the acknowledgment by the...

Series  RIKB 23 0515 RIKB 42 0217Settlement Date  05/25/2022 05/25/2022Total Amount Allocated (MM)  14,343 5,700All Bids Awarded At (Price / Simple interest)  96.090 / 5.750 90.443 / 5.290Total Number of Bids Received  33 12Total Amount of All Bids Received (MM)  16,543 6,850Total Number of Successful Bids  29 9Number of Bids Allocated in Full  29 9Lowest Price / Highest Simple Interest Allocated  96.090 / 5.750 90.443 / 5.290Highest Price / Lowest Simple Interest Allocated  96.210 / 5.610 90.600 / 5.280Lowest Price / Highest Simple Interest Allocated in Full  96.090 / 5.750 90.443 / 5.290Weighted Average of Successful Bids (Price/Simple Interest)  96.146 / 5.680 90.466 / 5.290Best Bid (Price / Simple Interest)  96.210 / 5.610 90.600 / 5.280Worst Bid (Price / Simple Interest)  95.990 / 5.860 90.218 / 5.310Weighted...

TORONTO, May 20, 2022 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) provides details of its 2022 annual and general meeting of shareholders (the “AGM”) to be held at Vu Restaurant located at 115 Ducksworth Street, St. John’s, Newfoundland and Labrador, A1C 1E9 at 4:00 p.m. NL Time (2:30 p.m. EST) on June 22, 2022. The AGM will be Marathon’s first held in person since 2019, and the first held by Marathon in the Province of Newfoundland and Labrador. Attendees of the meeting will be able to meet with Marathon management and board members, and receive an update on the development of the Valentine Gold Project from Matt Manson (President and CEO), Tim Williams (COO) and Julie Robertson (CFO). All registered shareholders, non-registered (or beneficial) shareholders, and duly appointed proxyholders...

GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) —  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5th Global NASH Congress on May 26-27, 2022, in London, UK. His presentation will provide an overview of pemvidutide, the Company’s novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and NASH. Dr. Harris will also moderate a panel discussion on clinical endpoints in NASH trials. Details for the oral presentation are as follows:Title: The Emerging Weight Loss Therapeutics and Implications for the NASH Treatment ParadigmPresenter: Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc.Date/Time: Friday, May 27, 2022 at 3:15 pm...

WATERTOWN, Mass., May 20, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, presented data demonstrating that the clinical stage selective IRAK4 degrader KT-474 degrades IRAK4 and inhibits cytokine production in different immune and skin cell types at the Society of Investigative Dermatology (SID) Annual Meeting 2022, taking place from May 18 – 21, 2022 in Portland, Oregon. The poster presentation highlights the broad impact of KT-474 across multiple disease-relevant cell types and supports the continued development of IRAK4 degraders in patients with HS, AD and other IL-1R/TLR-driven autoimmune diseases of the skin where IRAK4 plays a central role in the pathogenesis...

Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ET NEW YORK, May 20, 2022 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference taking place next week. A webcast of the presentation will be available for on demand download beginning on Tuesday, May 24, 2022, at 7:00 AM ET through Thursday May 26, 2022, on the conference website. The webcast will also be available on TG’s website at http://ir.tgtherapeutics.com/events. ABOUT TG THERAPEUTICS, INC.TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline...

– PTR-01 was well-tolerated over a four-month treatment period in RDEB patients – Treatment with PTR-01 led to rapid, consistent, and durable wound healing as observed in reduction of wound surface area and clinician-reported assessments – All patients that completed the study reported a decrease in pain over the course of treatment with PTR-01 PALO ALTO, Calif., May 20, 2022 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate company Phoenix Tissue Repair, which is focused on advancing a novel systemic treatment for recessive dystrophic epidermolysis bullosa (RDEB), announced data from the Phase 2 trial of PTR-01, an intravenously-administered recombinant collagen 7 (rC7) protein replacement therapy, in patients with recessive dystrophic epidermolysis bullosa (RDEB). The data are being shared...

Curtis will oversee all international operations for Mullen Automotive with a focus on existing company partnerships and new business opportunities for Mullen’s line of electric vehicles.Richard Curtis – President of International Operations Richard’s prior experience includes President of Imperium Motor Company and turnaround specialist for Lithia Motors.BREA, Calif., May 20, 2022 (GLOBE NEWSWIRE) — via InvestorWire — Mullen Automotive, Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces today the hiring of Richard Curtis to President of International Operations for Mullen Automotive.  Prior to joining Mullen Automotive, Curtis was the president of Imperium Motor Company. Prior to Imperium Motor Company, he served as a turnaround specialist for Lithia...